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ABSTRACT
Background: Gastric electrical stimulation has been
proven effective for drug-refractory gastroparesis. Place-
ment of stimulator leads and device usually requires a
laparotomy, although laparoscopic placement has also
been used.
Methods: To compare laparotomy with laparoscopy, we
examined 36 patients, 18 undergoing laparoscopy and 18
undergoing laparotomy, matched for primary diagnosis
and health resource usage. We compared baseline symp-
toms, length of surgery, length of postoperative hospital
stay, gastric emptying, and health resources in each of the
2 groups over time, to see what variables, if any, differed.
Results: Baseline symptoms, gastric emptying, and health
resource usage were similar. Operative times were also
similar, but length of stay declined from a mean of 6.4
days for laparotomy to 1.1 days for laparoscopy. Long-
term outcome, via symptoms, gastric emptying, and health
resource utilization were comparable between the 2
groups.
Conclusion: Laparoscopic placement of gastric electrical
stimulator leads and device is associated with shorter
lengths of postoperative hospital stay. However, the pa-
tients who underwent laparotomy had higher vomiting
scores and more previous abdominal surgeries at base-
line, and higher long-term mortality at follow-up, suggest-
ing that they may be more ill, as a group, than the lapa-
roscopic patients. Laparoscopic placement of devices may
be preferable when technically feasible.
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INTRODUCTION
Gastroparesis, a diverse disorder manifesting with symp-
toms of upper gut dysfunction/severe dyspepsia and dis-
ordered gastric emptying, can be difficult to treat. The
most commonly recognized cause for gastroparesis is the
neuropathy of long-term diabetes mellitus, although the
cause in many patients is of idiopathic or postsurgical
origin.1 The lack of effective gastro-kinetic drugs and the
loss of several drugs previously available has driven a
need for novel therapies. Patients with severe gastropare-
sis often suffer repeated hospitalizations, poor quality of
life, and many complications from the few available ther-
apies. Gastric electrical stimulation, which was introduced
in this form in January 1992 in Memphis Tennessee, has
recently been studied in a series of initial worldwide trials.
Gastric electrical stimulation (GES) has been shown to be
effective for drug-refractory gastroparesis (GP), as evi-
denced by a recent double-blind, randomized, placebo-
controlled study, and at 2 open label trials.2,3 However,
placement of a permanent GES device, since its inception
in the early 1990s, traditionally requires a laparotomy. The
introduction of laparoscopy offers the potential for shorter
hospitalizations, but it has not been clear whether the
long-term outcomes were equivalent to outcomes for
laparoscopy. We compared the operative times (OT),
length of stay (LOS), and long-term outcomes of 18 con-
secutive patients undergoing laparoscopic GES placement
(Lap) matched with 18 patients undergoing GES place-
ment by laparotomy (Open).
METHODS
Eighteen consecutive patients who had GP causes of di-
abetes mellitus, postsurgical and idiopathic disease under-
went laparoscopic (Lap) placement of a system for gastric
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SCIENTIFIC PAPERelectrical stimulation and were compared retrospectively
with 18 patients undergoing laparotomy (Open) for iden-
tical GES devices for primary diagnosis, past medical his-
tory, and health resource utilization from a group of ap-
proximately 50 implanted Open patients.4 The GES device
was an implantable neuromuscular stimulator (Medtronic
Itrel 3) programmed as follows: 330 microseconds, 12-
cpm burst frequency, with 5 milliAmperes of current, as
previously reported.2,3 This system was approved by the
FDA under Humanitarian Device Exemption regulations
in 2000, and this study protocol was approved by the
University of Arkansas Medical Center Institutional Re-
view Board. Open patients were taken primarily from a
group of GES patients who received an implanted inves-
tigational device at the University of Tennessee-Memphis,
where the device received IRB approval from 1995 to
2000. Written consent forms were obtained from all sub-
jects before the study. The patients at baseline were as-
sessed for a number of variables, including the number of
previous abdominal surgeries. After implantation of the
GES system (the gastric leads and the pulse generator),
symptom improvement was monitored by measurements
of Vomiting Frequency (VFS), Nausea Frequency (NFS)
scores, and their average (NAVS), (all ona0t o4scale,
none to worst); by total gastrointestinal (GI) symptom
scores (TSS), the sum of vomiting, nausea, bloating/dis-
tension, anorexia/early satiety, and abdominal pain (all
scored as 0 to 4, max score 20). Health resource utilization
was quantified by an Investigator Derived Independent
Outcome Measurement Score (IDIOMS), which quantifies
illness severity, health care services, and organ systems
involved, (each ona0t o1 0scale, maximum score 30) as
previously reported.4 Gastric emptying was measured by
a previously standardized low-fat meal and reported as
percentage of solid meal remaining at 4 hours.5 Operative
times (OT) in minutes were reported as noted in the
patient’s operative note, and postoperative hospital length
of stay (LOS) in hospital days after surgery were reported.
Symptom improvements, health resource measures, mea-
sures of gastric emptying (GET), operative times (OT),
length of stay (LOS), and long-term survival were reported
as mean  SE and compared by using t tests both within
(paired) and between (unpaired) groups.
For both laparoscopy and laparotomy, the surgical goals
were similar: gastric serosal electrodes were placed near
the body-antral junction, and the device was placed in a
subcutaneous pocket. Differences in surgical approach for
Lap and Open are noted in the Methods section below.
For Laparoscopy
The patient, after having been anesthetized and draped in
a sterile fashion, had an incision made just above the
umbilicus. This incision was carried down through the
fascia until the peritoneal cavity was entered. A Hasson
trocar was placed and pneumoperitoneum was achieved.
A 10-mm laparoscopic camera was inserted for intraperi-
toneal inspection to allow a 10-mm trocar catheter to be
placed in the left upper quadrant, and a 5-mm trocar
catheter in the right upper quadrant, both under direct
vision.
The distal stomach was identified, and the area 8 cm to10
cm proximal to the pylorus was isolated in preparation for
the placement of device leads. The stimulation leads,
having been prepared outside the body, were then at-
tached to the anterior gastric wall near the greater curva-
ture of the stomach. A sero-muscular partial thickness bite
was used to secure the electrodes, so that about 1cm of
exposed lead could be attached, leaving the electrode
secured in the muscle layers in the wall of the stomach.
The lead was then passed through a silastic disk and
clipped into place. The disk was tacked in place in 2
positions with suture, and the other end of the lead was
also attached to the stomach to prevent migration, using
3–0 silk. The second lead was placed in an identical
manner, about 1 cm from the first lead. Both ends of the
leads were then brought out through the 10-mm site in the
left upper quadrant. The skin incision was extended, and
a subcutaneous pocket was made. Before and after the
leads were attached to the pulse generator and then in-
serted into the pocket, the device was analyzed electron-
ically and when confirmed to be functioning well, the
pocket was closed with interrupted 3–0 Vicryl and then
running 4–0 Monocryl sutures.
The umbilical incision was closed with 0 Vicryl. The skin
was closed at all sites with 4–0 Monocryl and sterile
dressings were applied. Adequate generator function was
confirmed again before the operative procedure was com-
pleted.
For Laparotomy
As with laparoscopy, the patient was prepped, draped,
and anesthetized, and the abdomen was opened via an
upper midline incision with a controlled entrance into the
peritoneal cavity. The stomach was identified, inspected,
and appropriate sites for electrode placement were iden-
tified approximately 8cm proximal to the pylorus. The
stimulation leads were secured in a manner similar to that
described for laparoscopy above.
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stomach wall, the resistance to electrical stimulation was
measured electronically by temporarily attaching the leads
to the gastric stimulator, which was placed on the abdom-
inal wall. Gastric electrophysiology was recorded before
connecting the leads permanently to the device, to assure
that a good quality recording of gastric electrical activity
could be obtained from the stimulation leads. As with
laparoscopy, a subcutaneous pocket was created lateral to
the midline incision, and after passing the leads through
the abdominal wall fascia, the leads were once again
inserted in the device. An additional measurement of lead
impedance was then done before the pocket was closed.
The midline surgical wound was then closed in a standard
fashion.
RESULTS
Patients were followed up for a mean of 28.8 months in
the Lap group and 42.7 months in the Open group. The
patients were examined both for their baseline character-
istics and for results at the most recent follow-up. Patients
with missing data points were included, as long as fol-
low-up was present for at least 6 months.
The 2 patient groups were similar in age (40.8 years for
Lap vs 42.0 for Open) and slightly different in sex (6 m 12 f
i nL a pa n d2m1 6fi nOpen). However, fewer Lap patients
(6 of 18) had at least 1 previous abdominal surgery than
did the Open patients where 11 of 18 had previous ab-
dominal surgery.
At baseline, the patients with Lap had lower vomiting
scores than did the Open group (2.00.4 Vomiting Fre-
quency vs 3.60.2, Figure 1). The baseline nausea scores
were similar 3.60.2 Nausea Frequency Score vs 3.80.1,
(Figure 2) and the baseline average of nausea and vom-
iting was also less for the Lap patients, but the difference
was not as great as baseline vomiting (2.80.2 Nausea
and Vomiting Score vs 3.50.1, Figure 3).
The baseline TSS between the 2 groups was similar
(14.30.8 vs 16.81.2) as were the measures of health
resource utilization (17.21.0 vs 17.31.2).
Symptom improvement was similar in both groups, as was
improvement in gastric emptying, which is also noted in
Tables 1 and 2. At least one of the values of nausea,
vomiting, or nausea and vomiting was statistically signif-
icant for each group (Table 1). Symptom improvement in
the average of nausea and vomiting was from 2.80.2 to
2.20.3, P0.1 in the Lap group and from 3.50.1 to
2.90.3, P0.05 in the Open group. Symptom improve-
ment in the global measure of TSS was from 14.30.8 to
11.31.1, P0.05 in the Lap group and from 16.81.2 to
12.51.2, P0.004 in the Open group. (Figure 4)
Between-group improvements in symptoms were also
similar: average symptom improvement for Lap was 17.5%
vs average symptom improvement of 18% for Open.
Health resource measures in both groups of patients im-
Figure 1. Vomiting scores. The vomiting score was lower at
baseline for the Lap group but improved more at follow-up for
the Open group.
Figure 2. Nausea scores. The nausea scores improved more in
the Lap than Open group after gastric stimulation.
Figure 3. Comparison of combined nausea and vomiting pa-
rameters for Lap and Open groups at baseline and following
gastric stimulation.
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from 17.31.2 to 11.60.7, P0.001 in Open (Figure 5)
and were similar as were the between-group compari-
sons: average change 40% for Lap and 30% for Open.
At baseline, the patients with Lap as a group had less
retention in gastric emptying than did the Open patients
(GET 4 hour % 20.85.2 Lap vs 24.15.7 for Open)
P0.05. (Figure 6) The percentage of solid meal remain-
ing at 4 hours improved at latest follow-up (12.45.9 for
Lap and 8.48.8 for Open) P0.05. Examining the pa-
tients with delayed GET separately, the majority of pa-
tients with delayed GET improved at long-term follow-up
and mean values (percentage remaining at 4 hours for all
delayed patients in both groups) decreased from 26.0 at
baseline to 12.9 at latest follow-up.)
Operative times with Lap were comparable to those for
Open (Lap 103.68.2 min vs 99.310.2 min, P0.3, Fig-
ure 7). However, LOS was significantly shorter with Lap
Table 1.









N/V Baseline N/V Latest TSS Baseline TSS Latest
Lap 2.00.4 1.90.4 3.60.3 2.20.3 2.80.2 2.20.3 14.30.8 11.31.1
P Value 0.46 0.048 0.14 0.05
Open 3.60.2 30.3 3.80.1 3.61.7 3.50.1 2.90.3 16.8 12.5
P Value 0.03 0.11 0.04 0.004
Table 2.








4h rG E *
Baseline






Lap 17.21.0 10.20.7 40 20.85.2 12.45.9 103.68.2 1.10.1
P Value 0.001
Open 17.31.2 11.60.7 30 24.1 8.88.8 99.310.2 6.41.4
P Value 0.001
Lap/Open P Value 0.19 0.01
*IDIOMSInvestigator Derived Independent Outcome Measurement Score, GEgastric emptying, OToperative time, LOSlength of
hospital stay.
Figure 4. Total symptom score. The total symptoms score was
lower at baseline for the Lap group but improved more at
follow-up for the Open group.
Figure 5. Investigator Derived Independent Outcome Measure-
ment Score (IDIOMS). Significant improvement in the Investiga-
tor Derived Independent Outcome Measurement Score after
gastric stimulation in both groups.
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6.41.4 days, range 3 to 14 days, P0.01, Figure 8).
These data are summarized in the accompanying tables,
first, for subjective symptom measures and second, for
objective health resource, gastric emptying, OT, and LOS
data, and the accompanying graphs.
Over the reported period, 6 patients died, all in the Open
group. Five of these deaths were secondary to vascular
insults, including MI/CVA, pulmonary embolus, gastroin-
testinal tract infarction, intracranial bleeding related to
anticoagulation therapy, and line sepsis. Three patients
had devices replaced during the reported period: 1 in the
Lap group (related to an enteral tube replacement) and 2
in the Open group (one from a battery failure, and one
due to skin erosion.)
DISCUSSION
Gastric electrical stimulation (GES) based on the tech-
nique first applied in 19926,7 has been proven effective for
drug-refractory gastroparesis, and was approved as an
FDA Humanitarian Use Device (HUD) in 2000 for patients
with drug-refractory gastroparesis of idiopathic or diabetic
origin. This approval was based on 2 studies, one of
which at that point had not been completed, but that
showed promising long-term data. The first study (GEMS)2
showed an improvement in nausea and vomiting, using a
temporary phase where the device was worn externally,
followed by a longer-term study with implanted devices.
The results of that second (WAVESS)3 study, a random-
ized, double-blind, placebo-controlled, cross-over study,
have recently been published. The WAVESS study
showed a statistically significant reduction in vomiting
episodes with the device ON vs OFF. This improvement
continued through 1-year follow-up.
An additional study8 has shown short, intermediate, and
long-term nutritional benefits of a subset of the GEMS trial
followed closely over time. Other controlled trials are
underway, and a number of other studies relating to the
efficacy of GES in drug-refractory gastroparesis are either
underway or the results have been submitted for publica-
tion.
Of the 3 electrical stimulation methods advocated for
drug-refractory gastroparesis9 (gastric pacing-using high
energy and low frequency pulses, gastric electrical stimu-
lation-using low energy and high frequency pulses, and
sequential neural stimulation), only the second technique
(low-energy, high frequency stimulation) is currently
available and was the technique used in this study, as well
as the other studies referred to throughout this manu-
script.10
To compare the results of laparotomy (Open), the tradi-
tional technique used for placement of GES leads and
device in patients with drug-refractory gastroparesis, with
the results of similar patients who undergo a laparoscopic
(Lap) technique, we examined 36 patients, 18 Lap and 18
Open, retrospectively, matched for primary diagnosis and
health resource usage. We compared symptoms, gastric
emptying, health resource utilization, operative times, and
length of postoperative hospital stay, in each of the 2
groups to see what variables, if any, differed at baseline
and over time. However, the patients could not be
matched for the number of previous abdominal surgeries
as mentioned above.
Baseline total gastrointestinal symptoms, gastric empty-
Figure 6. Gastric emptying. Improvement in gastric emptying in
both groups following gastric stimulation but did not reach
significant P value.
Figure 7. Comparison of operative times for Open versus Lap
groups.
Figure 8. Length of stay. The length of stay is significantly less
for the Lap group.
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patients had higher vomiting and average of nausea and
vomiting scores, and had more previous abdominal sur-
geries. Operative times were similar in the 2 groups, but
length of stay was significantly shorter with Lap. Long-
term outcome of symptoms, gastric emptying, and health
resource utilization were generally comparable, and con-
sistent with that in other published reports.2 However, the
Open patients had more deaths during the time reported,
suggesting that they were more ill, as a group, than the
laparoscopic patients were in this study.
The improvements in gastric emptying times, although
worthy of mention, were not statistically significant. This
may be due, in part to the fact that at least 4 patients in
each group had nondelayed gastric emptying at baseline.
Many of the nondelayed patients had postsurgical gastro-
paresis and in fact had rapid emptying at baseline. It is
likely that the inclusion of the values from patients with
nondelayed emptying had an impact on the overall GET
results at most recent follow-up, as we have shown pre-
viously.11
CONCLUSION
We conclude that patients undergoing laparoscopic place-
ment of GES leads and device have shorter lengths of stay,
with most other variables being similar. However, the
patients who underwent laparotomy had higher vomiting
scores at baseline, more previous abdominal surgeries
and higher long-term mortality, with most deaths being
related to vascular access. Whether earlier (in the course
of symptomatic gastroparesis) placement of GES devices
would reduce the use of IV access, and possibly mortality,
is speculative, and cannot be answered by this report.
We also conclude that laparoscopic placement of GES
when feasible, involves shorter hospital stays, with com-
parable operative times. Improvements in symptom and
health resource measures were similar between the 2
groups, as were changes in the gastric emptying times.
However the patients in this report undergoing laparot-
omy may have been more ill at baseline, and had a higher
mortality at most recent follow-up. Based on the experi-
ence with these gastroparesis patients, laparoscopic
placement of GES should be considered whenever tech-
nically feasible. Continued improvement in laparoscopic
techniques and modifications of equipment for placement
GES devices and leads offer the potential for equivalent
care with lower hospital costs and equal or improved
patient outcomes.
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